up protherics
15 Dec 2017
And the And the spiv stock of the day Goes to BTG..Well it is pantomime season.. I expect the board will release a nice RNS shortly.
d gaser
13 Dec 2017
Northwestern Uni Adopts TheraSpher as first line treatment BTG plc: Northwestern University Adopts Y90 TARE with TheraSphere® as First-Line Treatment for HCCInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected] BTG plcBased on experience with 1000 patients over 15 years, the largest single-centre prospective, cohort of patients with HCC treated with Y90 glass microspheresLONDON, December 12, 2017 /PRNewswire/ --BTG plc (LSE: BTG), a global specialist healthcare company, today announced that following positive results of its 15-year experience between 2003 and 2017 with TheraSphere®, Northwestern University, Illinois has adopted Y90 transarterial radioembolisation (TARE) with TheraSphere® as the primary trans-arterial loco-regional therapy (LRT) for patients with hepatocellular carcinoma (HCC) limited to the liver.[1] (Logo: [link] )HCC is considered to be the most common primary liver cancer and represents the second most common cause of cancer mortality worldwide.[2] Northwestern University's decision to adopt TARE with TheraSphere® as a first-line transarterial LRT for patients with HCC was informed by data prospectively collected and incrementally reported, demonstrating outcomes as expected by the BCLC algorithm for stages A-D, applied as either neoadjuvant or definitive treatment. Compared with TACE, the data confirm that outpatient TARE allows for fewer treatments, better quality of life, longer time to progression and versatile application as neoadjuvant LRT combined with either resection or orthotopic liver transplantation.[1]"Patients are looking for treatments that are safe, efficacious, have minimal detrimental effects on their quality of life and as pain free as possible," said Dr Riad Salem, Chief, Section of Vascular & Interventional Radiology, Department of Radiology at Northwestern University and lead author of the paper "Institutional Decision to Adopt Y90 as Primary Treatment for HCC Informed by a 1,000-patient 15-year Experience" recently accepted for publication in Hepatology.[1] "The benefit of Y90 TARE with TheraSphere® is that it meets all of these patient needs, and also enables patients to be treated as outpatients, permitting discharge on the same day, reducing the need for lengthy hospitalisations and minimising impact on daily life. We recognise the many approaches to establishing a new standard of care. In our case, we are proud of the controlled, prospective studies we completed over the last decade, each addressing a specific question, and each getting us closer to the unanimous, multidisciplinary adoption of Y90 as first-line. We are hopeful that when colleagues and peers review the study, the long-term survival outcomes, our rationale and the strength of the evidence, many will follow suit."Peter Pattison, BTG General Manager Interventional Oncology, commented, "We are delighted that Northwestern University Hospital has chosen to adopt Y90 TARE with TheraSphere® as the first line trans-arterial LRT for patients with HCC. This first publication featuring over 1000 HCC patients treated with TheraSphere® represents a major milestone and we are proud to partner with healthcare professionals to deliver improved treatment options for patients."Since TARE Y90 was FDA approved in 1999 and made available for clinical use in early 2000, radiation therapy has become widely available as an effective option to treat HCC.[2] Treatment with Y90 TARE infuses TheraSphere® Y90 glass microspheres into the arteries that feed liver tumours. The microspheres deliver a targeted radiation dose to the tumour, minimising exposure to healthy tissue and can be adapted for each patient, allowing for a personalised treatment approach.About BTG Interventional Oncolo
up protherics
07 Dec 2017
Re: What going on ??? Pauloyou should be used to it by now.. Its the usual fall before a small jump then a crash after they release a negative RNS.. As I said in the past INMO this is now a spiv stock..If its any consolation I was suckered into buying Clinigen after Quanton pharma was sold out.. So in terms of spivs BTG still has some way to go, but I wouldn't be surprised if they catch them up soon.personally I will be out of this when it hits my target..Which at the moment seems way off.
pauloverdi
07 Dec 2017
What going on ??? I think BTG should change their name to Chinese Torture Plc !!! "DOES ANYBODY KNOW WHATS GOING ON" !!!Drip drip drip down every bl**dy day !! It's a joke especially as all the brokers are positive on the potential sales of the snake venom !!!This is a joke !! Let's hope the news conference today ay have something positive to say !!!I HAVE A DREAM !!!Goodness me this is so frustrating !!!Ciao Paulo
pauloverdi
27 Nov 2017
Unsure oMG I've like many have been in this share forever 10 years based upon Varisolve !! I'm sick and tired of looking in every day to see if there's movement. NOT !! Don't get me wrong I've made shed loads based upon the speculation but I'm so bored with it and am also thinking of getting out. I raised serious concerns over the years on the main board taking money out and never ever a dividend being offered. Don't need advice like yourselves but this is so tedious !!Kind regardsPauloIf I don't post again wish you all a very happy Christmas x
d gaser
27 Nov 2017
Another non excutive Director appointed BTG plc: have Appointment another Non-executive Director, at least this guy has sales and marketing experience, both in the US and emerging markets, but he has no experience in Europe or Asia according to the document , which is shame, as that is where we need to start selling our products What is with BTG and it's fear of Europe and Asia ? why can't this BOD see past the USA ? it's as if they are blind to other markets .At least this guy doe's have some experience in Sales &Marketing ,so hopefully, he will be able to pass on some valuable information to the present sales & Marketing Director, and his team of sales people. This appointment to me shows that BTG have no sales & marketing strategy, nor do they, have the knowledge to run such a department, this is bourn out by the wellstate debacle which cost BTG $55m,if this new guy can help sought out our marketing and sales dept. then he will be worth the extra cost ,but if not ,then it will more cash down the executive drain .BE HAPPYDAVE London, UK, 27 November 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board. Greg has a broad range of commercial experience in the US medtech industry, with a focus on interventional medicine therapies. He is currently a non-executive director of Cutera Inc and was previously President and Chief Executive Officer of DFINE Inc, Barrx Medical Inc, and ACMI Corporation. Prior roles include leading a minimally invasive surgery division of Boston Scientific, both in US and in emerging markets. Greg has also held a series of senior sales and marketing roles at a number of companies including Baxter Healthcare and C.R. Bard. Garry Watts, BTG's Chairman, commented: "Greg brings a strong track record to BTG, with significant US commercial and international medtech experience, which will be of great benefit to us as we continue to implement our growth plans." There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Conduct Authority Listing Rules. For further information contact:
innocent 2
22 Nov 2017
It was time for me to sell I got into this stock originally on the prospect of their 'varicose vein' treatment. This has gone hardly anywhere, and I think that it probably won't ever do much.I have stood by and watched on as Louise Makin and her cronies milked the company of fat bonuses and share issues with zero dividend income to the shareholders.At the same time I watched the share price oscillate up and down like a disjointed yoyo. I therefore decided to sell my holdings at £7.52 yesterday and re-invest the money in the hope of getting a better return.I may have made a mistake, but only time will tell
Tricky Rich
22 Nov 2017
Re: Strong half turm results . I too am a long term holder (although not posted in here for a while) and the recent results were strong and the market clearly likes them. I'd say the drop is to do with the JPM note reducing it's target from £7.50 to £7.30, albeit upgrading most estimates of numbers and re-iterating HOLD. Numis still think £9 and to me anything starting with a £7 is a comfortable place to be. It will require more info as the price is settling and let's see what comes out of the CMD on 7 Dec. All feeling pretty strong and well underpinned to me though...
up protherics
22 Nov 2017
Re: Strong half turm results . Sorry Mike,,butI am afraid this is now a spiv stock in the eyes of a lot of new investors together with long standing ones like myself.One half of the pantomime horse has gone. I myself hope the other half goes and a quick sale follows of the company to a suitor which now can add some value..Don't get me wrong the existing board did well up until three years ago. However they were handsomely rewarded for their efforts.. Even though they managed to offload some shares before negative RNS followed.Todays drop is interesting.. Probably a institution dumping stock or even worse some other mess up by the board.
Mike Land
20 Nov 2017
Re: Strong half turm results . Come on guys. The market has viewed the results as good and the share price is up. Just what we need!!
Mike Land
16 Nov 2017
Re: Strong half turm results . Invesco seem to have reduced their holding by 1% so is this the beginning of a long and slow unloading and taking profit? If so bad news for us other guys unless the sales are into a rising market.
up protherics
15 Nov 2017
Re: Strong half turm results . DaveI agree entirely with your viewsRudderless ship is rapidly springing to mind.INMO The other half of the pantomime horse should have gone.. Its behind you.. Still there is nothing like a Dame.Basically they have messed up the past 3 years and inmo the share price is only at this level due to institutions still holding. For reasons which I hope we all find out shortly.Take a look at Clinigen.. Thats another one which inmo has sucked a few investors in of la
d gaser
15 Nov 2017
Re: Strong half turm results . I'm sorry but I can't see any advantage in concentrating on the US market as being the best policy ,the European union as we all know consists of 28 countries, and its controlled by the EMA ,which is Europe's equivalent of the FDA, and is based here in the UK see link below www.ema.europa.eu/ema/index.jspcurl=pages/special_topics/general/general_content_000489.jsp&mid=WC0b01ac058060676fThey also work with the FDA in regards to trials, they can also accelerate drug clearance when a product has been given FDA clearance if they so wish .so I don't see any advantage from just sticking to the USA as any market as big as Europe's can not be left out of any companies growth predictions.I would also say, most sales and marketing companies' in this area of expertise all ready offer a good service to US companies' ,and work hard to sell their products under licence right across Europe ,and they make excellent profits, for them self's and the companies they work with . Personally I can't see any reason why BTG couldn't employ a UK and European sales team of their own ,while at the same time, taking on other licenced products to sell along side their own, A.G.Y can do it very successfully, as can VEC and smiths, plus, many other big pharmaceutical companies, and remember, licencing good products can also bring big rewards, not every company is sued for bad workmanship, or for breaking their contract ,smiths for instance have been doing it for years, and do very well out of it.In your post you suggest, that maybe some body in the USA is looking BTG over ,with a view to taking us over ,if that was the case,then wouldn't our C.F.O know some thing about such a take over ? if that was the case then why is he stepping down, wouldn't he not remain in place until such a deal was concluded, just in case you were not aware : BTG plc announces that after 10 years as Chief Financial Officer (CFO) at BTG, Rolf Soderstrom is to step down as an Executive Director of the Company. The Board intends to appoint Duncan Kennedy to succeed Rolf as CFO on 1 January 2018. Rolf will remain with the Company until completion of a smooth handover to Duncan, which is expected to be concluded by 31 March 2018.full story see link www.iii.co.uk/research/LSE:BTG/news/item/2577557/directorate-change?context=LSE:BTGPersonally I have no idea why the board are not interested in Europe or the rest of the world ,all I do know, is Europe is missing out on our technology ,and we are missing out on the profit we could be generating there ,and it's also holding back growth. Obviously this is just my view, but I would be interested to hear what other shareholders views are regarding this subject .BE HAPPYDAVE .
Mike Land
14 Nov 2017
Re: Strong half turm results . Product licences around the world are not really helped by USA ones. Actually UK ones can be better! Europe is a very expensive market as in sales it is lots of individual markets all different to operate in. We like tablets, the Italians injections the French suppositories. And remember the USA sales are supported by an in house sales team. If you use distributors you give away most of the local profit and have to make money on manufacturing and royalty type profits which can be much smaller.With all the clear cost of the USA presence - hence the lost legal case because even there they had to stop promoting the less important product and suffered the damages they are probably right to concentrate there. I also suspect that is where they see the eventual sale of the business.Remember the owners are fund managers who will be pushing for an exit soon. Who will buy? Anyone who wants to develop a strong presence in the USA who is not there already for which BTG is a strong base or any US company wanting to expand their presence.Either way the lack of a Europe or ROW strategy suggests to me they are near to sale ......And the buyer gets a pile of cash as well.
d gaser
14 Nov 2017
Strong half turm results . Looking through this set of results,they appear to be very good ,as predicted sales in the US are up .Product sales are 17% and were driven by Interventional Oncology, Interventional Vascular and Pharmaceutical there was also Strong growth in the adjusted operating profit, but operating profit declined by 36% this was due to the fine we incurred (£53.5m) following the final court ruling regarding the Wellstat litigation, how ever ,the company Continued to deliver strong cash generation, with free cash flow up 35% ,had it not been for the wellstat debacle ,I believe, the company is moving in the right direction .The only thing I'm not sure about is the move to drop G.B.P for reporting audits, and sales figures in the future, the board in their wisdom have decided to use the U.S.D instead, this I fear could be the beginning of a major shift regarding ,BTG intention of moving much of their production act to the USA , It could also mean, BTG, intend to concentrate on the USA market only , and would explain why the company is so reluctance to gain E.U clearance for some of our other drugs/procedures such as Varithena®. To me, this company in the past has not taken advantage of Europe ,Australia, Asia ,south America and Africa,in fact, Geographical analysis show that BTG only sold £21.09m of goods in to Europe ,that's less than £1M to each of the European countries that's shocking , and they only sold £7m of goods to the rest of the world ,now that's unbelievable for a company like BTG, but in the USA,BTG sold £341.03m in Six months, now just think to your self's just how much could our turn over figure have been, had we been trading with the rest of the world in the same way, as we are in the USA?and how much would BTG be worth now had we engaged the rest of the world ?.Can any body out there tell me why we ignore the rest of the world ? and just concentrate on north America, especially as we all know most countries will automatically offer clearance to a drug or mechanical device that has all ready received FDA clearance? Or they fast track it, so why do BTG disregard 70% of the worlds markets that are open to them ? While your thinking about that, its good to see BTG have maintained their mark up at about 69% and have not reduced it in order to gain market share.BE HAPPYDAVE
